Xin Lang Cai Jing·2025-10-31 05:33Core Insights - Zhaoyan New Drug's stock increased by 5.12% to 37.18 CNY per share, with a trading volume of 999 million CNY and a turnover rate of 4.41%, resulting in a total market capitalization of 27.866 billion CNY [1] Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. was established on February 25, 1998, and listed on August 25, 2017. The company primarily focuses on non-clinical safety evaluation services for drugs and sales of preclinical research services and laboratory animals [1] - The main revenue composition includes: 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from laboratory model supply [1] Fund Holdings - According to data, one fund under Rongtong Fund has a significant holding in Zhaoyan New Drug. The Rongtong Healthcare Industry Mixed A/B Fund (161616) reduced its holdings by 318,500 shares in the third quarter, now holding 938,300 shares, which accounts for 3.95% of the fund's net value, ranking as the sixth-largest holding [2] - The Rongtong Healthcare Industry Mixed A/B Fund was established on July 26, 2012, with a latest scale of 708 million CNY. Year-to-date returns are 12.74%, ranking 5494 out of 8154 in its category; the one-year return is 8.38%, ranking 6220 out of 8046; and since inception, the return is 136.09% [2] Fund Manager Information - The fund managers of Rongtong Healthcare Industry Mixed A/B Fund are Wan Minyuan and Liu Xiyang. Wan Minyuan has a tenure of 9 years and 69 days, managing assets totaling 5.957 billion CNY, with the best fund return of 144.04% and the worst return of -20.09% during his tenure [3] - Liu Xiyang has a tenure of 1 year and 231 days, managing assets totaling 839 million CNY, with the best fund return of -1.31% and the worst return of -2.08% during his tenure [3]